149 related articles for article (PubMed ID: 25934841)
1. Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.
Bunch DO; Mendoza CE; Aybar LT; Kotzen ES; Colby KR; Hu Y; Hogan SL; Poulton CJ; Schmitz JL; Falk RJ; Nachman PH; Pendergraft WF; McGregor JG
Ann Rheum Dis; 2015 Sep; 74(9):1784-6. PubMed ID: 25934841
[No Abstract] [Full Text] [Related]
2. Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.
Bunch DO; McGregor JG; Khandoobhai NB; Aybar LT; Burkart ME; Hu Y; Hogan SL; Poulton CJ; Berg EA; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2013 Mar; 8(3):382-91. PubMed ID: 23293123
[TBL] [Abstract][Full Text] [Related]
3. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
Md Yusof MY; Vital EM; Das S; Dass S; Arumugakani G; Savic S; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Sep; 74(9):1734-8. PubMed ID: 25854586
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
[TBL] [Abstract][Full Text] [Related]
6. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
8. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
9. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
10. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
Clain JM; Specks U
Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713
[No Abstract] [Full Text] [Related]
11. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
Pendergraft WF; Cortazar FB; Wenger J; Murphy AP; Rhee EP; Laliberte KA; Niles JL
Clin J Am Soc Nephrol; 2014 Apr; 9(4):736-44. PubMed ID: 24626432
[TBL] [Abstract][Full Text] [Related]
12. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
13. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
14. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
15. [Use of rituximab in the induction of remission of severe, resistant and recurrent form of polyangiitis associated with c-ANCA antibodies - case report].
Brodowska-Kania D; Rymarz A; Saracyn M; Geisler P; Niemczyk S
Pol Merkur Lekarski; 2015 Apr; 38(226):216-8. PubMed ID: 25938389
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapy for ANCA-associated vasculitis.
Geetha D; Seo P
Curr Rheumatol Rep; 2012 Dec; 14(6):509-15. PubMed ID: 22895899
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab (MabThera): a new therapy for ANCA vasculitis].
von Frenckell C; Delanaye P
Rev Med Liege; 2015 Feb; 70(2):92-100. PubMed ID: 26011994
[TBL] [Abstract][Full Text] [Related]
19. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
